3SBio Inc
HKEX:1530

Watchlist Manager
3SBio Inc Logo
3SBio Inc
HKEX:1530
Watchlist
Price: 27.88 HKD -0.92%
Market Cap: 67.8B HKD

3SBio Inc
Total Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

3SBio Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
3SBio Inc
HKEX:1530
Total Assets
ÂĄ23.8B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Assets
ÂĄ42.8B
CAGR 3-Years
-8%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Assets
ÂĄ23.6B
CAGR 3-Years
13%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Assets
ÂĄ12.8B
CAGR 3-Years
38%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Assets
ÂĄ14.7B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Total Assets
ÂĄ3.5B
CAGR 3-Years
63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

3SBio Inc
Glance View

Market Cap
65.8B HKD
Industry
Biotechnology

3SBio Inc., founded in 1993, is a prominent player in the biopharmaceutical landscape of China. Driven by a mission to improve human health quality through biopharmaceutical innovation, the company has cultivated a robust portfolio of products, primarily focusing on three key therapeutic areas: oncology, nephrology, and autoimmune diseases. At the core of 3SBio's operations is its strong emphasis on research and development, with several state-of-the-art facilities where it continuously explores advancements in biological medicines. These efforts have positioned the company as a leader in the production of recombinant proteins and antibodies, which are essential in treating chronic and life-threatening conditions. 3SBio derives its revenue through a well-integrated business model that spans drug development, manufacturing, and commercialization. This model allows the company not only to generate income from its diverse product offerings but also to leverage strategic partnerships and licensing agreements, both locally and internationally. Their flagship products, such as EPIAO, a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, and TPIAO, a thrombopoietin receptor agonist used in the management of idiopathic thrombocytopenic purpura, are among the top revenue drivers. By maintaining a strong pipeline of both innovative and biosimilar products, 3SBio ensures sustained profitability and growth, meeting the ever-evolving demands of healthcare systems and patients worldwide. Amidst the competitive and rapidly evolving biotech industry, 3SBio stands out with its commitment to quality and innovation, anchored by a strategic vision to expand its influence beyond traditional boundaries.

Intrinsic Value
41.44 HKD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is 3SBio Inc's Total Assets?
Total Assets
23.8B CNY

Based on the financial report for Jun 30, 2025, 3SBio Inc's Total Assets amounts to 23.8B CNY.

What is 3SBio Inc's Total Assets growth rate?
Total Assets CAGR 5Y
6%

Over the last year, the Total Assets growth was 0%. The average annual Total Assets growth rates for 3SBio Inc have been 5% over the past three years , 6% over the past five years .

Back to Top